Price
Target price
€9.99
€9.99
1.940%
0.19
1.940%
€47.44
11:24 / Tradegate
WKN: A2AG6H / Symbol: NTLA / Name: Intellia / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Intellia Therapeutics Inc Stock
Intellia Therapeutics Inc gained 1.940% today.
The stock is one of the favorites of our community with 23 Buy predictions and 3 Sell predictions.
Based on the current price of 9.99 € the target price of 47 € shows a potential of 370.56% for Intellia Therapeutics Inc which would more than double the current price.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Intellia Therapeutics Inc stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Intellia Therapeutics Inc in the next few years
Pros
?
B****
?
G***** c******* t* c**********
?
S********** s********
Cons
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Intellia Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Intellia Therapeutics Inc | 1.940% | 6.570% | -15.352% | -53.630% | -13.788% | -84.609% | -44.424% |
| Chromadex Corp | -1.740% | -4.678% | 3.165% | 157.911% | 58.252% | 434.952% | 81.920% |
| Polynovo Ltd | 12.390% | -10.317% | -17.518% | -63.312% | -53.306% | -58.759% | -59.929% |
| Cardio3 Biosciences S.A. | -1.100% | 6.452% | 10.671% | 82.412% | -45.083% | -81.940% | -95.642% |
Comments
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at Royal Bank Of Canada from $25.00 to $21.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at HC Wainwright from $30.00 to $25.00. They now have a "buy" rating on the stock.
Show more
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "overweight" rating re-affirmed by analysts at Wells Fargo & Company.
Show more
Ratings data for NTLA provided by MarketBeat
News
Intellia (NTLA) Q2 Revenue Jumps 106%
Intellia Therapeutics (NASDAQ:NTLA), a biotechnology company developing CRISPR-based gene-editing therapies, reported second quarter 2025 results on August 7, 2025. The headline news was a
Analysts Think These Stocks Could More Than Double in Value
Persistent volatility has plagued the S&P 500 for much of 2025, prompting widespread caution among many investors amid the uncertainties of trade battles, tariffs, domestic policy, and more
Intellia Therapeutics Delivers a Q4 Beat
Intellia Therapeutics (NASDAQ:NTLA), a leader in gene-editing technology, delivered its fourth-quarter earnings results on Feb. 27. The company reported a net loss of $1.27 per share, which was